TFS Capital’s Cascadian Therapeutics CASC Stock Holding History
Bought
Maintained
Sold
Other funds holding CASC
SH
TFS Capital's CASC Position: Q3 2017 in Review
TFS Capital sold out of Cascadian Therapeutics (CASC) in Q3 2017, closing a stake of 62,283 shares — an estimated $231K sold.
TFS Capital first reported a position in CASC in Q2 2013 and held it in 15 quarters. The position peaked at $1.08M in Q1 2014. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.
- TFS Capital reported no remaining Cascadian Therapeutics position as of Q3 2017 after selling out during the quarter.
- TFS Capital sold 62,283 Cascadian Therapeutics shares in Q3 2017, an estimated $231K.
- TFS Capital first reported a position in Cascadian Therapeutics in Q2 2013 and held it in 15 quarters.
- TFS Capital's Cascadian Therapeutics position peaked at $1.08M in Q1 2014.
- 79 funds tracked by Wall St. Rank held Cascadian Therapeutics as of Q3 2017.
Based on TFS Capital's 13F filing for Q3 2017.